Get the Stockscreener App
91.51
1.88%
1.69
After Hours:
91.52
0.010
+0.01%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $91.51, with a volume of 6.10M.
It is up +1.88% in the last 24 hours and up +4.61% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$89.82
Open:
$91.18
24h Volume:
6.10M
Relative Volume:
1.17
Market Cap:
$283.73B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
30.39
EPS:
3.0113
Net Cash Flow:
$9.87B
1W Performance:
+0.73%
1M Performance:
+4.61%
6M Performance:
+23.95%
1Y Performance:
+36.22%
1-Day Range:
$89.70
$91.66
1-Week Range:
$89.67
$91.66
52-Week Range:
$61.24
$94.02
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
91.51 | 278.49B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Why is AstraZeneca PLC (AZN) One of the Best Pharma Stocks to Invest In? - Insider Monkey
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma (AZN) - Seeking Alpha
Aug Ideas: Will Precidian ETFs Trust AstraZeneca PLC stock maintain strong growthJuly 2025 Sector Moves & Smart Allocation Stock Reports - BỘ NỘI VỤ
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Benzinga
AstraZeneca price target raised to $105 from $95 at TD Cowen on growth outlook - Investing.com UK
AstraZeneca (AZN) Begins Phase 3 Trial of Enhertu for Ovarian Ca - GuruFocus
Quantbot Technologies LP Reduces Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Hsbc Holdings PLC - MarketBeat
Cerity Partners LLC Increases Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca (LSE:AZN): Assessing Valuation After a Strong Year-to-Date Share Price Rally - Yahoo Finance
AstraZeneca PLC (NASDAQ:AZN) Nasdaq Futures Science-Driven Growth - Kalkine Media
AstraZeneca PLC ADR Rises Monday, Outperforms Market - 富途牛牛
Pillar Biosciences and AstraZeneca expand liquid biopsy access partnership to China - marketscreener.com
Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China - marketscreener.com
AstraZeneca is top pharma tip for 2026, with GSK left trailing - Proactive Investors
How Are AstraZeneca’s Scientific Initiatives Influencing Its FTSE 100 Standing? - Kalkine Media
AstraZeneca (AZN) Price Target Raised by JPMorgan - GuruFocus
First Trust Advisors LP Acquires 217,595 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Bought by Invesco Ltd. - MarketBeat
1832 Asset Management L.P. Acquires 18,543 Shares of AstraZeneca PLC $AZN - MarketBeat
Surprises Report: Is AstraZeneca PLC ZEG stock resilient in recession scenariosLong Setup & High Accuracy Investment Signals - BỘ NỘI VỤ
AstraZeneca PLC $AZN Shares Sold by Capital Fund Management S.A. - MarketBeat
AstraZeneca: An Insight Into The Growth Potential Of Imfinzi - Smartkarma
SCS Capital Management LLC Purchases 142,331 Shares of AstraZeneca PLC $AZN - MarketBeat
Marshall Wace LLP Buys 623,902 Shares of AstraZeneca PLC $AZN - MarketBeat
Guggenheim Capital LLC Has $13.58 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
UK stocks gain ahead of key US inflation data; AstraZeneca rises - marketscreener.com
Is AstraZeneca PLC (Common Stock) (ZEGA) stock a buy on weaknessWeekly Profit Summary & Fast Gain Stock Tips - Newser
Epoch Investment Partners Inc. Trims Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca selects Salesforce’s Agentforce for global HCP engagement By Investing.com - Investing.com Nigeria
Is Precidian ETFs Trust AstraZeneca PLC stock a top dividend aristocrat candidateTrade Risk Assessment & Expert Approved Momentum Trade Ideas - Newser
Why Precidian ETFs Trust AstraZeneca PLC stock benefits from AI revolutionQuarterly Investment Review & AI Enhanced Execution Alerts - Newser
Has AstraZeneca’s Strong 30% Rally Left Further Upside in 2025? - Yahoo Finance
Salesforce’s Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement - Yahoo Finance
AstraZeneca Stake Adjustment by Capital Group - TipRanks
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Sahm
ASTRAZENECA : Bernstein remains its Buy rating - marketscreener.com
FDA Streamlines Clinical Study Requirements, Impacting AstraZene - GuruFocus
AstraZeneca (AZN) Could Benefit from FDA's Shift to Single Study Approval - GuruFocus
REGAstraZeneca PLCHolding(s) in Company - TradingView
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH - marketscreener.com
Neurimmune expands collaboration with AstraZeneca to develop and commercialize Fibril Depleter NI009 for AL Amyloidosis - marketscreener.com
AstraZeneca news live: price tests Ichimoku Kijun support — bullish momentum meets consolidation risks - Traders Union
M&T Bank Corp Has $15.30 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
Bernstein Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Raises Target Price to $245.46 - 富途牛牛
AstraZeneca PLC Advances Hematology and Cell Therapy Ambition with Largest-Ever Presence at ASH - marketscreener.com
AstraZeneca (AZN) Set to Showcase Hematology Innovations at ASH 2025 - GuruFocus
New York State Common Retirement Fund Has $13.74 Million Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca to showcase hematology advances at ASH annual meeting By Investing.com - Investing.com UK
Arrowstreet Capital Limited Partnership Cuts Position in AstraZeneca PLC $AZN - MarketBeat
Guggenheim Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Raises Target Price to $206.76 - 富途牛牛
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):